RxDoctor Payments Data

Jenny Ho, DO

Family Medicine · Glendale, AZNPI 1427315506

Payments from drug & device makers

$1,001in general payments, 2019–2025

Across 27 payments — averaging $37.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$379
  • AbbVie$140
  • Lilly USA, LLC$136
  • Johnson & Johnson$112
  • Abbott$53
  • Pfizer$46
  • plus $135 from 5 others

What the payments were for

  • Food & beverage$1,001100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,001 in reported general payments places this provider in the 70th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$96,693
Medicare patients
224
Services billed
2,600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$101,805
JardianceEmpagliflozin70$95,012
RybelsusSemaglutide22$39,523
TrulicityDulaglutide21$39,217
MyrbetriqMirabegron34$26,095
EliquisApixaban19$24,749
MounjaroTirzepatide16$22,679
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$14,567
ShingrixVaricella-Zoster Ge/As01b/Pf57$12,664
FarxigaDapagliflozin Propanediol12$9,249
Breo ElliptaFluticasone/Vilanterol12$6,579
LantusInsulin Glargine,hum.Rec.Anlog14$4,421
Rosuvastatin Calcium274$4,407
HumalogInsulin Lispro21$4,335
Nateglinide30$3,752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$379$141,32892 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$136$66,23158 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta$34$33,81088 claims
PfizerEliquis$46$24,74919 claims
AbbVieSynthroid$140$1,45134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →